DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
1404
LITIFILIMAB
3
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
LITIFILIMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
GUMOKIMAB
3
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
GUMOKIMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FAVEZELIMAB
3
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
FAVEZELIMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TULISOKIBART
3
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
TULISOKIBART
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ROSMANTUZUMAB
3
Antibody
Investigational
Unknown
Unknown
Neoplasms
RSPO3-LGR4 inhibitor
ROSMANTUZUMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
VD026R6TCI
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ANIFROLUMAB
3
Antibody
Investigational
Unknown
Unknown
Scleroderma, Localized; Arthritis, Rheumatoid; Lupus Nephritis; Lupus Erythematosus, Systemic
Interferon-alpha/beta receptor alpha chain antagonist
ANIFROLUMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
38RL9AE51Q
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CASIRIVIMAB
3
Antibody
Investigational
Unknown
Unknown
Severe Acute Respiratory Syndrome
Unknown
CASIRIVIMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TOSATOXUMAB
3
Antibody
Investigational
Unknown
Unknown
Pneumonia, Staphylococcal
Unknown
TOSATOXUMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
6AA3OC17QR
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PEMTUMOMAB
3
Antibody
Investigational
Unknown
Unknown
Unknown
Mucin-1 binding agent
PEMTUMOMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
VOLRUSTOMIG
3
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
VOLRUSTOMIG
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IMGN853
3
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
IMGN853
×
Maximum Phase:
3
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TEZEPELUMAB
3
Antibody
Investigational
Unknown
Unknown
Hypersensitivity; Dermatitis, Atopic; Pulmonary Disease, Chronic Obstructive; Urticaria; Asthma
Thymic stromal lymphopoietin inhibitor
TEZEPELUMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
RJ1IW3B4QX
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
CG250 111IN
3
Antibody
Investigational
Unknown
Unknown
Carcinoma, Renal Cell
Carbonic anhydrase IX binding agent
CG250 111IN
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BERMEKIMAB
3
Antibody
Investigational
Unknown
Unknown
Acne Vulgaris; Dermatitis, Atopic; Diabetes Mellitus, Type 2; Hidradenitis Suppurativa; Psoriasis; Pyoderma; Scleroderma, Systemic; Colorectal Neoplasms; Neoplasms
Interleukin-1 alpha inhibitor
BERMEKIMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
N6SVN735GY
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
JNJ-63723283
3
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
JNJ-63723283
×
Maximum Phase:
3
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OTELIXIZUMAB
3
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Graves Ophthalmopathy; Diabetes Mellitus, Type 1
T-cell surface glycoprotein CD3 epsilon chain binding agent
OTELIXIZUMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
I5HF2X04PB
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FREXALIMAB
3
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
FREXALIMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PUCOTENLIMAB
3
Antibody
Investigational
Unknown
Unknown
Neoplasms; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; Melanoma; Thyroid Neoplasms; Urinary Bladder Neoplasms; Stomach Neoplasms
Programmed cell death protein 1 inhibitor
PUCOTENLIMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TARCOCIMAB
3
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
TARCOCIMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
EFUNGUMAB
3
Antibody
Investigational
Unknown
Unknown
Breast Neoplasms; Meningitis, Cryptococcal
Heat shock protein 90 homolog inhibitor
EFUNGUMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
BM86P708HW
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LEVILIMAB
3
Antibody
Investigational
Unknown
Unknown
Arthritis, Rheumatoid; Severe Acute Respiratory Syndrome
Interleukin-6 receptor alpha subunit inhibitor
LEVILIMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
P7UV3L2H80
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DOSTARLIMAB
3
Antibody
Investigational
Unknown
Unknown
Multiple Myeloma; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Pancreatic Ductal; Head and Neck Neoplasms; Hemangiosarcoma; Hereditary Breast and Ovarian Cancer Syndrome; Liver Neoplasms; Melanoma; Mesothelioma; Pancreatic Neoplasms; Rectal Neoplasms; Sarcoma; Small Cell Lung Carcinoma; Uterine Cervical Neoplasms; Ovarian Neoplasms; Endometrial Neoplasms; Neoplasms
Programmed cell death protein 1 antagonist
DOSTARLIMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
P0GVQ9A4S5
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LATOZINEMAB
3
Antibody
Investigational
Unknown
Unknown
Frontotemporal Dementia
Unknown
LATOZINEMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IZALONTAMAB
3
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
IZALONTAMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MOTAVIZUMAB
3
Antibody
Investigational
Unknown
Unknown
Hernias, Diaphragmatic, Congenital; Respiratory Sounds; Respiratory Syncytial Virus Infections
Fusion glycoprotein F0 inhibitor
MOTAVIZUMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
50Y163LK8Q
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
FELZARTAMAB
3
Antibody
Investigational
Unknown
Unknown
Glomerulonephritis, Membranous; Glomerulonephritis; Kidney Diseases; Multiple Myeloma
Lymphocyte differentiation antigen CD38 inhibitor
FELZARTAMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
DEPEMOKIMAB
3
Antibody
Investigational
Unknown
Unknown
Asthma
Unknown
DEPEMOKIMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
OREGOVOMAB
3
Antibody
Investigational
Unknown
Unknown
Fallopian Tube Neoplasms; Peritoneal Neoplasms; Ovarian Neoplasms
Mucin-16 other
OREGOVOMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
HX101E7L6S
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
BIRTAMIMAB
3
Antibody
Investigational
Unknown
Unknown
Amyloidosis; Amyloidosis, Familial
Light chain aggregates inhibitor
BIRTAMIMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
VXQ2SK8I3P
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LY3074828
3
Antibody
Investigational
Unknown
Unknown
Unknown
Unknown
LY3074828
×
Maximum Phase:
3
First Approval:
None
UNII:
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IODINE I 131 APAMISTAMAB
3
Antibody
Investigational
Unknown
Unknown
Leukemia, Myeloid, Acute
Unknown
IODINE I 131 APAMISTAMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LINTUZUMAB
3
Antibody
Investigational
Unknown
Unknown
Leukemia, Myelomonocytic, Chronic; Multiple Myeloma; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Neutropenia; Leukemia
Myeloid cell surface antigen CD33 other
LINTUZUMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
V00Y10W60W
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LEBRIKIZUMAB
3
Antibody
Investigational
Unknown
Unknown
Idiopathic Pulmonary Fibrosis; Pulmonary Disease, Chronic Obstructive; Asthma; Dermatitis, Atopic
Interleukin-13 inhibitor
LEBRIKIZUMAB
×
Maximum Phase:
3
First Approval:
None
UNII:
U9JLP7V031
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
MEVONLERBART
3
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
MEVONLERBART
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
UMESOLERBART
3
Antibody
Unknown
Unknown
Unknown
Unknown
Unknown
UMESOLERBART
×
Maximum Phase:
3
First Approval:
None
UNII:
None
Molecule Type:
Antibody
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
33
34
35
36
37
38
39
40
41
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA